Aripiprazole Tablet
Product Images NDC 43598-734

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 43598-734). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1.jpg (Aripiprazole Figure1)

The text provides a table of the effect of different drugs on Aripiprazole, presented as fold change and 90% confidence interval. The drugs evaluated include CYP3A4 and CYP2DE inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs such as Viproste, lithium, and Lorazepam. The data indicates the change relative to a reference without the interacting drug.*

FDA Label Image

Figure-2.jpg (Aripiprazole Figure2)

This is a table indicating the effect of different drugs on the medication Aripiprazole, with their corresponding PK values and their ability to inhibit or induce certain enzymes. The Dehydro-Aripiprazole Fold Change and 90% CI have also been provided, indicating the relative change in the medication's effects in the presence of these drugs.*

FDA Label Image

Figure-3.jpg (Aripiprazole Figure3)

The text is discussing the effect of Aripiprazole, a drug, on the performance of other drugs such as dextromethorphan, Warfarin, Omeprazole, Venlafaxine, Lithium, and Lorazepam. The fold change and 90% C1 relative to the reference are given for each drug, but the actual values are not available.*

FDA Label Image

Figure-4.jpg (Aripiprazole Figure4)

This is a table that seems to describe the effects of different conditions on the pharmacokinetics of a drug called aripiprazole. It looks at how factors such as genetics (CYP2D6 phenotype), gender, age, and liver or renal impairment affect the drug's maximum concentration (Cmax) and area under the curve (AUC). There also appears to be data on the change in aripiprazole levels and a confidence interval (90% CI). However, the purpose or context of this information is not available.*

FDA Label Image

Figure-5.jpg (Aripiprazole Figure5)

This appears to be a table displaying the fold change and 80% confidence interval of PK Dehydro-Aripiprazole for various factors such as CYP2D6 metabolizer status, gender, age, and hepatic/renal impairment. The values seem to compare the AUC and Cmax of different groups against a reference group. However, without further context or explanation, it is difficult to interpret the data meaningfully.*

FDA Label Image

Figure-6.jpg (Aripiprazole Figure6)

This appears to be a graph or table showing the proportion of subjects who experienced a relapse while taking Aripiprazole compared to a placebo. The table also includes the number of subjects at risk over time for both treatment groups. The x-axis appears to measure the number of days from randomization.*

FDA Label Image

Figure 7 (Aripiprazole Figure7)

FDA Label Image

Figure 8 (Aripiprazole Figure8)

This appears to be a chart showing the proportion of subjects experiencing relapse over time for two groups: those receiving aripiprazole and those receiving a placebo. The chart also shows the number of subjects at risk at each time point. There is no additional information available.*

FDA Label Image

10mg-30 (Aripiprazole Label1)

FDA Label Image

15mg-30 (Aripiprazole Label2)

This text seems to be a mix of different types of data. It includes some distorted characters, special characters, symbols, some numerical data, and incomplete or unclear phrases. Therefore, it is not possible to generate a useful description.*

FDA Label Image

Structural Formula (Aripiprazole Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.